エビデンスに基づく急速進行性腎炎症候群(RPGN)診療ガイドライン2014

出版社： 東京医学社
著者：
発行日： 2014-12-20
分野： 臨床医学：内科  >  腎臓
ISBN： 9784885632471
電子書籍版： 2014-12-20
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する
特記事項：
  • 【電子書籍】電子書籍版にはCD－ROMは付属しません。ご了承ください。

目次

  • エビデンスに基づく急速進行性腎炎症候群（RPGN）
    診療ガイドライン2014

    ―目次―

    1．疾患概念・定義（病因・病態生理）
    　疾患概念・定義（病因・病態生理）

    2．診断
    　症候学・症状・検査所見

    3．疫学・予後
    　発症率・有病率・治療成績

    4．治療
    　1．治療に関するアルゴリズム
    　2．診断・治療に関するCQ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 疾患概念・定義 ( 病因・病態生理 )

P.6 掲載の参考文献
a. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
1. Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
b. Koyama A, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009 ; 13 : 633-50.
PubMed
2. Pedchenko V, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010 ; 363 : 343-54.
PubMed
3. Levy JB, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004 ; 66 : 1535-40.
PubMed
c. Churg J, et al. Classification of glomerular disease. In : Churg J, et al (eds). Renal disease. Classification and atlas of glomerular diseases. 2nd ed, Igaku-Shoin : New York, Tokyo, 1995, p11.
 
4. Rutgers A, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005 ; 46 : 253-62.
PubMed
d. Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
e. Couser WG. Rapidly progressive glomerulonephritis : classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988 ; 11 : 449-64.
 
5. Yang R, et al. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2007 ; 18 : 1338-43.
 
f. 尾崎承一, 他 : ANCA関連血管炎の診療ガイドライン, 2011.
 
6. Olson SW, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011 ; 22 : 1946-52.
PubMed
g. Walker RG, et al. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. Q J Med 1985 ; 54 : 75-89.
 
7. Belmont HM, et al. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996 ; 39 : 9-22.
PubMed
h. Chen M, et al. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol 2007 ; 18 : 599-605.
 
i. Tsuchiya N, et al : Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis : association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol 2003 ; 30 : 1534-40.
PubMed
j. Falk RJ, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990 ; 87 : 4115-9.
 
k. Arimura Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993 ; 40 : 256-64.
 
l. 川嶋聡子, 他 : MPO-ANCA関連腎炎における糸球体内MPO陽性細胞及び細胞外MPOについての腎病理組織学的検討. 日腎会誌 2009 ; 51 : 56-67.
 
m. Kessenbrock K, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009 ; 15 : 623-5.
 

II 診断

P.19 掲載の参考文献
1. 厚生労働省特定疾患進行性腎障害に関する調査研究班報告. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
2. 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 : 55-82.
 
3. Shigematsu H, et al. Glomerulointerstitial events in rapidly progressive nephritic syndrome, with special reference to histologic grade and stage on the renal lesions : Clin Exp Nephrol 1998 ; 2 : 330-8.
 
4. Joh K, et al. Renal pathology of ANCA-related vasculitis : Proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 2008 ; 12 : 277-91.
PubMed
5. Berden AE, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010 ; 21 : 1628-36.
PubMed
6. Chang DY, et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis : a study of 121 patients in a single center. Nephrol Dial Transplant 2012 ; 27 : 2343-9.
 
7. Muso E, et al. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of MPO-ANCA-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol 2013 ; 17 : 659-62.
 
8. Kussmaul A, et al. Ubereinenichtbisherbeschriebeneeigenthumliche Arterienerkrankung (Periarteritisnodosa) , diemitMorbusBrightii und rapid fortschreitenderallgemeiner-Muskelahmungeinhergeht. Deutsche Archiv KlinischeMedizin 1866 ; 1 : 484-518.
 
9. Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990 ; 33 : 11017.
 
10. Jennette JC, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994 ; 37 : 187-92.
PubMed
11. 吉田雅治, 他. 中・小型血管炎の臨床に関する小委員会報告厚生省特定疾患免疫疾患調査研究班難治性血管炎分科会平成10年度報告書. 1999 ; 239-46.
 
12. Koyama A, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009 ; 13 : 633-50.
PubMed
13. 天野宏一. アレルギー性肉芽腫性血管炎 (Churg Strauss症候群) の本邦における実態解明に関する研究. 厚生労働科学研究費補助金難治性血管炎に関する調査研究平成21年度総括・分担研究報告書. 2010 : 98-9.
 
14. Watts R, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007 ; 66 : 222-7.
PubMed
15. 山村昌弘, 他. ANCA 関連血管炎前向き観察コホート研究「抗好中球細胞質抗体 (ANCA) 関連血管炎の寛解導入治療の現状とその有効性と安全性に関する観察研究 (RemIT-JAV) 」実施計画の策定, 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 平成20年度研究終了報告書. 2009 ; 77-102.
 
16. Pankhurst T, et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004 ; 43 : 1532-5.
PubMed
17. 軽部美穂, 他. ANCA関連血管炎と悪性腫瘍. Annual Review腎臓 2007. 東京 : 中外医学社, 2007 ; 69-75.
 
18. Naicker S, et al. Infection and glomerulonephritis. Semin Immunopathol 2007 ; 29 : 397-414.
PubMed
19. Iwata Y, et al. Shunt nephritis with positive titers for ANCA specific for proteinase 3. Am J Kidney Dis 2004 ; 43 : e11-16.
PubMed
20. Koyama A, et al. Glomerulonephritis associated with MRSA infection : a possible role of bacterial superantigen. Kidney Int 1995 ; 47 : 207-16.
PubMed

III 疫学・予後

P.23 掲載の参考文献
1. 遠藤正之, 他. 進行性腎障害4疾患の患者推計およびIgA腎症疫学調査. 厚生労働科学研究費補助金難治性疾患克服研究事業進行性腎障害に関する調査研究平成16年度総括・分担研究報告書. 2005, 163-7.
 
2. 渡辺毅, 他. 全国疫学アンケート調査とDPCデータベースの対象疾患患者数調査への応用. 厚生労働科学研究費補助金難治性疾患克服研究事業進行性腎障害に関する調査研究平成23年度総括・分担研究報告書. 2012, 53-62.
 
3. Sugiyama H, et al. Japan Renal Biopsy Registry : the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 2011 ; 15 : 493-503.
PubMed
4. 横山仁, 他. 腎臓病総合レジストリーの構築とその解析. 厚生労働科学研究費補助金難治性疾患克服研究事業進行性腎障害に関する調査研究平成20-22年総合研究報告書. 2011 ; 17-22.
 
5. 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況 (2011年12月31日現在). 日本透析医学会ホームページ (http://www.jsdt.or.jp)
 
6. Lopez-Gomez JM, et al ; Spanish Registry of Glomerulonephritis. Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish Registry of Glomerulonephritis. Clin J Am Soc Nephrol 2008 ; 3 : 674-81.
PubMed
7. McQuarrie EP, et al. Centre variation in incidence, indication and diagnosis of adult native renal biopsy in Scotland. Nephrol Dial Transplant 2009 ; 24 : 1524-8.
PubMed
8. Hedger N, et al. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK : a 10-year retrospective study. Nephrol Dial Transplant 2000 ; 15 : 1593-9.
 
9. 松尾清一, 他. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
10. Koyama A, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009 ; 13 : 633-50.
PubMed
11. Day CJ, et al. Prediction of ESRD in pauci-immune necrotizing glomerulonephritis : quantitative histomorphometric assessment and serum creatine. Am J Kidney Dis 2010 ; 55 : 250-8.
 

IV 治療

P.28 掲載の参考文献
1. Hagen EC, et al. Kidney Int 1998 ; 53 : 743-53. (レベル 4)
 
2. Csernok E, et al. Rheumatology (Oxford) 2004 ; 43 : 174-80. (レベル 4)
 
3. Holle JU, et al. Ann Rheum Dis 2005 ; 64 : 1773-9. (レベル 4)
 
4. Trevisin M, et al. Am J Clin Pathol 2008 ; 129 : 42-53. (レベル 4)
 
5. Ito-Ihara T, et al. Clin Exp Rheumatol 2008 ; 26 : 1027-33. (レベル 4)
 
a. Davies DJ, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology. Brit Med J 1982 ; 285 : 606.
 
b. van der Woude FJ, et al. Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985 ; 1 : 425.
 
c. Tervaert JW, et al. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing : do we need to revise the international consensus statement on testing and reporting on ANCA? APMIS Suppl 2009 ; (127) : 55-9.
 
d. Savige J, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999 ; 111 : 507-13.
 
e. Mukhtyar C, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
f. Csernok E, et al. Twenty-years with ANCA : how to test for ANCA-evidence based immunology? Autoimmunity Highlights 2010 ; 1 : 39-45.
 
g. Suzuki K, et al. Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol 2007 ; 51 : 1215-20.
 
h. Roth AJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013 ; 123 : 1773-83.
 
P.32 掲載の参考文献
1. Han WK, et al. Kidney Int 2003 ; 63 : 1079-85. (レベル 4)
 
2. Tomasson G, et al. Rheumatology (Oxford) 2012 ; 51 : 100-9. (レベル 1)
 
a. van der Woude FJ, et al. Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985 ; 1 : 425-9.
 
b. Gaskin G, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991 ; 6 : 689-94.
 
c. Pettersson E, et al. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis : a longitudinal study. Clin Nephrol 1992 ; 37 : 219-28.
PubMed
d. Girard T, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001 ; 40 : 147-51.
 
e. Kerr GS, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993 ; 36 : 365-71.
 
f. Finkielman JD, et al ; WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007 ; 147 : 611-9.
 
g. Lapraik C, et al ; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
h. Terrier B, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009 ; 68 : 1564-71.
 
i. 有村義宏, 他. ANCA関連血管炎とRPGN. 日腎会誌 2009 ; 51 : 88-93.
 
P.34 掲載の参考文献
1. Lockwood CM, et al. Lancet 1976 ; 1 (7962) : 711-5. (レベル 5)
 
2. Johnson JP, et al. Am J Med 1978 ; 64 : 354-9. (レベル 5)
 
3. Johnson JP, et al. Medicine (Baltimore) 1985 ; 64 : 219-27. (レベル 2)
 
4. Yang R, et al. Nephrol Dial Transplant 2009 ; 24 : 1838-44. (レベル 4)
 
5. Pedchenko V, et al. N Engl J Med 2010 ; 363 : 343-54. (レベル 4)
 
6. Jia XY, et al. Clin J Am Soc Nephrol 2012 ; 7 : 926-33. (レベル 4)
 
7. Herody M, et al. Clin Nephrol 1993 ; 40 : 249-55. (レベル 4)
 
8. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
9. Cui Z, et al. Medicine (Baltimore) 2011 ; 90 : 303-11. (レベル 4)
 
10. Levy JB, et al. Am J Kidney Dis 1996 ; 27 : 573-8. (レベル 5)
 
11. Kalluri R, et al. Transplantation 2000 ; 69 : 679-83.
PubMed
a. Pedchenko V, et al. Goodpasture's disease ; molecular architecture of the autoantigen provides clues to etiology and pathogenesis. Curr Opin Nephrol Hypertens 2011 ; 20 : 290-6.
PubMed
b. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針. 日腎会誌 2011 ; 53 : 509-55.
 
c. Hirayama K, et al. Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 2008 ; 12 : 339-47.
 
P.37 掲載の参考文献
1. Bajema IM, et al. Kidney Int 1999 ; 56 : 1751-8. (レベル 4)
 
2. Vergunst CE, et al. Am J Kidney Dis 2003 ; 41 : 532-8. (レベル 4)
 
3. de Lind van Wijngaarden RA, et al. J Am Soc Nephrol 2006 ; 17 : 2264-74. (レベル 2)
 
4. Day CJ, et al. Am J Kidney Dis 2010 ; 55 : 250-8. (レベル 4)
 
5. Hauer HA, et al. Kidney Int 2002 ; 62 : 1732-42. (レベル 4)
 
6. de Lind van Wijngaarden RA, et al. J Am Soc Nephrol 2007 ; 18 : 2189-97. (レベル 2)
 
7. Berden AE, et al. J Am Soc Nephrol 2010 ; 21 : 1628-36. (レベル 4)
 
8. Muso E, et al. Clin Exp Nephrol 2013 ; 17 : 659-62. (レベル 4)
 
9. Pagnoux C, et al. Arthritis Rheum 2010 ; 62 : 616-26. (レベル 4)
 
10. Inoue M, et al. Hum Pathol 1998 ; 29 : 223-7. (レベル 5)
 
11. Bajema IM, et al. Nephrol Dial Transplant 1996 ; 11 : 1989-95. (レベル 4)
 
12. Joh K, et al. Clin Exp Nephrol 2008 ; 12 : 277-91. (レベル 4)
 
13. Johnson JP, et al. Medicin (e Baltimore) 1985 ; 64 : 219-27. (レベル 2)
 
14. Merkel F, et al. Nephrol Dial Transplant 1994 ; 9 : 372-6. (レベル 4)
 
15. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
16. Walker RG, et al. Q J Med 1985 ; 54 : 75-89. (レベル 4)
 
a. 今井裕一. 腎生検におけるインフォームド・コンセント. 日腎会誌 2005 ; 47 : 76-82.
 
b. 日本腎臓学会・腎生検検討委員会編. 腎生検ガイドブック : より安全な腎生検を施行するために. 東京医学社, 2004.
 
c. 平方秀樹. 腎生検の適応と禁忌. 日腎会誌 2005 ; 47 : 73-5.
 
d. 尾崎承一, 他. ANCA 関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業 2011.
 
e. 松尾清一, 他. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
f. 堺秀人, 他. 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 ; 55-82.
 
g. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
h. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis : evidence-based recommendations. Kidney Int Suppl 1999 ; 70 : S33-40.
 
i. KDIGO Clinical Practice Guideline. Kidney Int 2012 ; Suppl 2 : 233-42.
 
P.38 掲載の参考文献
1. Hedger N, et al. Nephrol Dial Transplant 2000 ; 15 : 1593-9. (レベル 4)
 
2. Chen M, et al. J Am Soc Nephrol 2007 ; 18 : 599-605. (レベル 4)
 
3. Hauer HA, et al. Kidney Int 2002 ; 61 : 80-9. (レベル 5)
 
a. 厚生労働省特定疾患進行性腎障害に関する調査研究班報告. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
P.40 掲載の参考文献
1. Yamagata K, et al. Clin Exp Nephrol 2012 ; 16 : 580-8. (レベル 4)
 
2. Harper L, et al. Rheumatology (Oxford) 2005 ; 44 : 495-501. (レベル 4)
 
3. Pagnoux C, et al. Arthritis Rheum 2008 ; 58 : 2908-18. (レベル 4)
 
a. 厚生労働省特定疾患進行性腎障害に関する調査研究班報告. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
b. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
c. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
d. 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 : 55-82.
 
P.41 掲載の参考文献
1. Harper L, et al. Rheumatology (Oxford) 2005 ; 44 : 495-501. (レベル 4)
 
2. Yamagata K, et al. Clin Exp Nephrol 2012 ; 16 : 580-8. (レベル 4)
 
a. 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 : 55-82.
 
b. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
c. 厚生労働省特定疾患進行性腎障害に関する調査研究班報告. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
P.46 掲載の参考文献
1. Frohnert PP, et al. Am J Med 1967 ; 43 : 8-14. (レベル 5)
 
2. Bolton WK, et al. Am J Med 1979 ; 66 : 495-502. (レベル 5)
 
3. Couser WG. Am J Nephrol 1982 ; 2 : 57-69. (レベル 5)
 
4. Nachman PH, et al. J Am Soc Nephrol 1996 ; 7 : 33-9. (レベル 3)
 
5. Hogan SL, et al. Ann Intern Med 2005 ; 143 : 621-31. (レベル 4)
 
6. Adu D, et al. QJM 1997 ; 90 : 401-9. (レベル 2)
 
7. Lionaki S, et al. Kidney Int 2009 ; 76 : 644-51. (レベル 4)
 
8. Bolton WK, et al. Am J Nephrol 1989 ; 9 : 368-75. (レベル 4)
 
9. Hogan SL, et al. J Am Soc Nephrol 1996 ; 7 : 23-32. (レベル 4)
 
10. de Lind van Wijngaarden RA, et al. J Am Soc Nephrol 2006 ; 17 : 2264-74. (レベル 4)
 
11. Austin HA III, et al. N Engl J Med 1986 ; 314 : 614-9. (レベル 2)
 
12. Gourley MF, et al. Ann Intern Med 1996 ; 125 : 549-57. (レベル 2)
 
13. Cui Z, et al. Medicine (Baltimore) 2011 ; 90 : 303-11. (レベル 4)
 
14. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
15. Johnson JP, et al. Medicin (e Baltimore) 1985 ; 64 : 219-27. (レベル 2)
 
a. Walters GD, et al. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010 ; 11 : 12.
 
b. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
c. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
d. Menahem S, et al ; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2008 ; 13 Suppl 2 : S24-36.
 
e. KIDIGO Clinical Practice Guideline. Anti-glomerular basement membrane antibody glomerulonephritis. Kidney Int 2012 (Suppl 2) : 233-42.
 
f. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
g. 尾崎承一, 他編. ANCA関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業, 2011.
 
h. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
i. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012 ; 71 : 1771-82.
 
j. Lupus nephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (suppl 2) : 221-32.
 
k. Hirayama K, et al. Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 2008 ; 12 : 339-47.
PubMed
l. Anti-glomerular basement membrane antibody glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (suppl 2) : 240-2.
 
P.49 掲載の参考文献
1. Adu D, et al. QJM 1997 ; 90 : 401-9. (レベル 2)
 
2. Bolton WK, et al. Am J Nephrol 1989 ; 9 : 368-75. (レベル 4)
 
3. Jayne DR, et al. J Am Soc Nephrol 2007 ; 18 : 2180-8. (レベル 2)
 
4. Austin HA III, et al. N Engl J Med 1986 ; 314 : 614-9. (レベル 2)
 
5. Gourley MF, et al. Ann Intern Med 1996 ; 125 : 549-57. (レベル 2)
 
6. Houssiau FA, et al. Arthritis Rheum 2002 ; 46 : 2121-31. (レベル 2)
 
7. Mok CC, et al. Am J Kidney Dis 2001 ; 38 : 256-64. (レベル 3)
 
8. Appel GB, et al. J Am Soc Nephrol 2009 ; 20 : 1103-12. (レベル 2)
 
9. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
10. Johnson JP, et al. Medicin (e Baltimore) 1985 ; 64 : 219-27. (レベル 2)
 
11. Cui Z, et al. Medicine (Baltimore) 2011 ; 90 : 303-11. (レベル 4)
 
a. Pauci-immune focal and segmental necrotizing glomerulonephritis in KDIGO Clinical Practice Guideline. Kidney Int 2012 (Suppl 2) : 233-42.
 
b. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
c. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
d. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012 ; 71 : 1771-82.
 
e. Lupus nephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (suppl 2) : 221-32.
 
f. Hirayama K, et al. Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 2008 ; 12 : 339-47.
 
g. Anti-glomerular basement membrane antibody glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (suppl) ; 2 : 240-2.
 
P.54 掲載の参考文献
1. Nachman PH, et al. J Am Soc Nephrol 1996 ; 7 : 33-9. (レベル 3)
 
2. Hogan SL, et al. J Am Soc Nephrol 1996 ; 7 : 23-32. (レベル 3)
 
3. De Groot K, et al. Arthritis Rheum 2005 ; 52 : 2461-9. (レベル 2)
 
4. Steinberg AD, et al. Arthritis Rheum 1991 ; 34 : 945-50. (レベル 2)
 
5. Houssiau FA, et al. Arthritis Rheum 2002 ; 46 : 2121-31. (レベル 2)
 
6. Houssiau FA, et al. Ann Rheum Dis 2010 ; 69 : 61-4. (レベル 2)
 
7. Chan TM, et al. N Engl J Med 2000 ; 343 : 1156-62. (レベル 2)
 
8. Ginzler EM, et al. N Engl J Med 2005 ; 353 : 2219-28. (レベル 2)
 
9. Kamanamool N, et al. Medicine (Baltimore) 2010 ; 89 : 227-35. (レベル 1)
 
10. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
11. Cui Z, et al. Medicine (Baltimore) 2011 ; 90 : 303-11. (レベル 4)
 
a. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
b. Walters GD, et al. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010 ; 11 : 12.
 
c. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 ; Suppl 2 : 233-42.
 
d. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
e. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
f. Menahem S. et al ; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2008 ; 13 Suppl 2 : S24-36.
 
g. 尾崎承一, 他編. ANCA 関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業, 2011.
 
h. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
i. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012 ; 71 : 1771-82.
 
P.55 掲載の参考文献
1. de Groot K, et al. Ann Intern Med 2009 ; 150 : 670-80. (レベル 2)
 
2. Adu D, et al. QJM 1997 ; 90 : 401-9. (レベル 2)
 
3. Guillevin L, et al. Arthritis Rheum 1997 ; 40 : 2187-98. (レベル 2)
 
4. Haubitz M, et al. Arthritis Rheum 1998 ; 41 : 1835-44. (レベル 2)
 
5. Walters GD, et al. BMC Nephrol 2010 ; 11 : 12. (レベル 1)
 
a. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
PubMed
b. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
c. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 ; Suppl 2 : 233-42.
 
d. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
P.58 掲載の参考文献
1. Jayne DR, et al. J Am Soc Nephrol 2007 ; 18 : 2180-8. (レベル 2)
 
2. Pepper RJ, et al. Clin J Am Soc Nephrol 2013 ; 8 : 219-24. (レベル 4)
 
3. de Lind van Wijngaarden RA, et al. J Am Soc Nephrol 2006 ; 17 : 2264-74. (レベル 2)
 
4. de Lind van Wijngaarden RA, et al. J Am Soc Nephrol 2007 ; 18 : 2189-97. (レベル 2)
 
5. Kamanamool N, et al. Medicine (Baltimore) 2010 ; 89 : 227-35. (レベル 1)
 
6. Liang L, et al. J Rheumatol 2004 ; 31 : 701-6. (レベル 4)
 
7. Hind C, et al. Lancet 1983 ; (1 8319) : 263-5. (レベル 4)
 
8. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
9. Flores JC, et al. Lancet 1986 ; (1 8471) : 5-8. (レベル 5)
 
a. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
PubMed
b. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-
 
c. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
d. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012 ; 71 : 1771-82.
 
P.63 掲載の参考文献
1. Specks U, et al. Arthritis Rheum 2001 ; 44 : 2836-40. (レベル 5)
 
2. Keogh KA, et al. Am J Respir Crit Care Med 2006 ; 173 : 180-7. (レベル 4)
 
3. Jones RB, et al. N Engl J Med 2010 ; 363 : 211-20. (レベル 2)
 
4. Stone JH, et al. N Engl J Med 2010 ; 363 : 221-32. (レベル 2)
 
5. Jones RB, et al. Arthritis Rheum 2009 ; 60 : 2156-68. (レベル 4)
 
6. Berden AE, et al. J Am Soc Nephrol 2012 ; 23 : 313-21. (レベル 4)
 
7. Specks U, et al. N Engl J Med 2013 ; 369 : 417-27. (レベル 2)
 
8. Gregersen JW, et al. Scand J Rheumatol 2013 ; 42 : 207-10. (レベル 4)
 
9. Mansfield N, et al. Nephrol Dial Transplant 2011 ; 26 : 3280-6. (レベル 4)
 
10. Cartin-Ceba R, et al. Arthritis Rheum 2012 ; 64 : 3770-8. (レベル 4)
 
11. Rhee EP, et al. Clin J Am Soc Nephrol 2010 ; 5 : 1394-400. (レベル 4)
 
12. Diaz-Lagares C, et al. Autoimmun Rev 2012 ; 11 : 357-64. (レベル 4)
 
13. Jonsdottir T, et al. Rheumatology (Oxford) 2013 ; 52 : 847-55. (レベル 4)
 
14. Melander C, et al. Clin J Am Soc Nephrol 2009 ; 4 : 579-87. (レベル 4)
 
15. Rovin BH, et al. Arthritis Rheum 2012 ; 64 : 1215-26. (レベル 2)
 
16. Pepper R, et al. Nephrol Dial Transplant 2009 ; 24 : 3717-23. (レベル 4)
 
17. Condon MB, et al. Ann Rheum Dis 2013 ; 72 : 1280-6. (レベル 4)
 
18. Li EK, et al. Rheumatology (Oxford) 2009 ; 48 : 892-8. (レベル 2)
 
19. Syeda UA, et al. Semin Arthritis Rheum 2013 ; 42 : 567-72. (レベル 5)
 
a. La Presse Medicale & Quarterly Medial Review 42 : 4 : 768-78, 2013 (abstracts, 16th International Vasculitis & ANCA Workshop).
 
b. 尾崎承一, 他編. ANCA関連血管炎の診療ガイドライン. p83, 厚生労働省難治性疾患克服事業, 2011.
 
c. 尾崎承一. RiCRAV 報告. 厚生労働省AAVのわが国における治療法の確立のための多施設共同前向き臨床研究. 第21年度総括・分担研究報告書. 2010 ; 99-102.
 
d. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
e. Pauci-immune focal and segmental necrotizing glomerulonephritis in KDIGO Clinical Practice Guideline. Kidney Int 2012 (Suppl 2) ; 233-42.
 
f. Guerry MJ, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012 ; 51 : 634-43.
 
g. Gregersen JW, et al. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012 ; 8 : 505-14.
 
h. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
i. Lupus nephritis in KDIGO Clinical Practice Guideline for Gloemerulonephritis. Kidney Int 2012 (suppl 2) : 221-32.
 
j. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012 ; 71 : 1771-82.
 
P.66 掲載の参考文献
1. Jayne DR, et al. J Am Soc Nephrol 2007 ; 18 : 2180-8. (レベル 2)
 
2. Szpirt WM, et al. Nephrol Dial Transplant 2011 ; 26 : 206-13. (レベル 2)
 
3. Walters GD, et al. BMC Nephrol 2010 ; 11 : 12. (レベル 1)
 
4. Walsh M, et al. Am J Kidney Dis 2011 ; 57 : 566-74. (レベル 1)
 
5. Yamagata K, et al. J Clin Apher 2005 ; 20 : 244-51. (レベル 4)
 
6. Wei N, et al. Lancet 1983 ; 1 (8314-5) : 17-22. (レベル 2)
 
7. Lewis EJ, et al. N Engl J Med 1992 ; 326 : 1373-9. (レベル 2)
 
8. Euler HH, et al. Arthritis Rheum 1994 ; 37 : 1784-94. (レベル 5)
 
9. Yamaji K, et al. Ther Apher Dial 2008 ; 12 : 298-305. (レベル 5)
 
10. Loo CY, et al. Transfus Apher Sci 2010 ; 43 : 335-40. (レベル 2)
 
11. Cui Z, et al. Medicine (Baltimore) 2011 ; 90 : 303-11. (レベル 4)
 
12. Flores JC, et al. Lancet 1986 ; 1 (8471) : 5-8. (レベル 5)
 
a. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
PubMed
b. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
c. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 ; Suppl 2 : 233-42.
 
d. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
P.69 掲載の参考文献
1. BP Silfverskiold. Scand Arch Physiol 1940 ; 175-82.
 
2. Kleinerman J. Lab Invest 1954 ; 3 : 495-508.
PubMed
3. Vassalli P, et al. Am J Pathol 1964 ; 45 : 653-77.
PubMed
4. Halpern B, et al. Nature 1965 ; 205 : 257-9.
PubMed
5. Kincaid-Smith P, et al. Lancet 1968 ; 2 (7583) : 1360-3. (レベル 5)
 
6. Arieff AI, et al. Arch Intern Med 1972 ; 129 : 77-84. (レベル 5)
 
7. Brown CB, et al. Lancet 1974 ; 2 (7890) : 1166-72. (レベル 5)
 
8. Fye KH, et al. Arch Intern Med 1976 ; 136 : 995-9. (レベル 5)
 
9. Cunningham RJ III, et al. Pediatr Res 1980 ; 14 : 128-32. (レベル 5)
 
10. Hirahashi J, et al. Ann Intern Med 2012 ; 156 : 755-6. (レベル 5)
 
11. Taji Y, et al. Clin Exp Nephrol 2006 ; 10 : 268-73.
PubMed
12. Liu XJ, et al. Intern Med 2011 ; 50 : 2503-10.
PubMed
13. Kessenbrock K, et al. Nat Med 2009 ; 15 : 623-5.
PubMed
14. Hakkim A, et al. Proc Natl Acad Sci U S A 2010 ; 107 : 9813-8.
PubMed
15. Clark SR, et al. Nat Med 2007 ; 13 : 463-9.
PubMed
16. Fuchs TA, et al. Proc Natl Acad Sci U S A 2010 ; 107 : 15880-5.
PubMed
P.71 掲載の参考文献
1. Martinez V, et al ; French Vasculitis Study Group. Arthritis Rheum 2008 ; 58 : 308-17. (レベル 3)
 
2. Jayne DR, et al. QJM 2000 ; 93 : 433-9. (レベル 2)
 
3. Muso E, et al. Jpn J Infect Dis 2004 ; 57 : S17-8. (レベル 3)
 
4. Ito-Ihara T, et al. Nephron Clin Pract 2006 ; 102 : c35-42. (レベル 3)
 
a. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012 ; 367 : 2015-25.
PubMed
b. Schwab I, et al. Intravenous immunoglobulin therapy : how does IgG modulate the immune system? Nat Rev Immunol 2013 ; 13 : 176-89.
 
c. Jayne DR, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991 ; 337 : 1137-9.
PubMed
d. Richter C, et al. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993 ; 336 : 487-9.
 
e. Jayne DR, et al. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996 ; 35 : 1150-3.
 
f. Levy Y, et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999 ; 92 : 412-4.
 
g. Fortin PM, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2013 ; 1 : CD007057.
PubMed
h. Lapraik C, et al ; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
i. Mukhtyar C, et al ; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
j. Tsurikisawa N, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004 ; 92 : 80-7.
 
k. Taniguchi M, et al. Treatment for Churg-Strauss syndrome : induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 2007 ; 56 : 97-103.
 
P.73 掲載の参考文献
1. Frohnert PP, et al. Am J Med 1967 ; 43 : 8-14. (レベル 4)
 
2. Bolton WK, et al. Am J Med 1979 ; 66 : 495-502. (レベル 4)
 
3. Couser WG. Am J Nephrol 1982 ; 2 : 57-69. (レベル 5)
 
4. Bolton WK, et al. Am J Nephrol 1989 ; 9 : 368-75. (レベル 4)
 
5. Nachman PH, et al. J Am Soc Nephrol 1996 ; 7 : 33-9. (レベル 3)
 
6. Adu D, et al. QJM 1997 ; 90 : 401-9. (レベル 2)
 
7. Walsh M, et al. Arthritis Care Res 2010 ; 62 : 1166-73. (レベル 1)
 
8. Ozaki S, et al. Mod Rheumatol 2012 ; 22 : 394-404. (レベル 4)
 
9. Austin HA III, et al. N Engl J Med 1986 ; 314 : 614-9. (レベル 2)
 
10. Gourley MF, et al. Ann Intern Med 1996 ; 125 : 549-57. (レベル 2)
 
11. Houssiau FA, et al. Arthritis Rheum 2002 ; 46 : 2121-31. (レベル 2)
 
12. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
a. Walters GD, et al. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010 ; 11 : 12.
 
b. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
c. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
d. Menahem S, et al ; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2008 ; 13 Suppl 2 : S24-36.
 
e. Pauci-immune focal and segmental necrotizing glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 233-9.
 
f. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
g. 尾崎承一, 他編. ANCA 関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業, 2011.
 
h. Turnbull J, et al. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009 ; 23 : 391-401.
 
i. Hahn BH, et al. American College of Rheumatology Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
PubMed
j. Lupus nephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 221-32.
 
k. Anti-glomerular basement membrane antibody glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 240-2.
 
P.75 掲載の参考文献
1. Walsh M, et al. Arthritis Care Res 2010 ; 62 : 1166-73. (レベル 1)
 
2. Jayne D, et al. N Engl J Med 2003 ; 349 : 36-44. (レベル 2)
 
3. Wada T, et al. J Rheumatol 2012 ; 39 : 545-51. (レベル 4)
 
4. Ozaki S, et al. Mod Rheumatol 2012 ; 22 : 394-404. (レベル 4)
 
a. Walters GD, et al. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010 ; 11 : 12.
 
b. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
 
c. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
d. Menahem S, et al ; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis. Nephrology (Carlton) 2008 ; 13 Suppl 2 : S24-36.
 
e. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 ; Suppl 2 : 233-42.
 
f. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌2011 ; 53 : 509-55.
 
g. 尾崎承一, 他編. ANCA 関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業, 2011.
 
h. Turnbull J, et al. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009 ; 23 : 391-401.
 
P.78 掲載の参考文献
1. Jayne D, et al. N Engl J Med 2003 ; 349 : 36-44. (レベル 2)
 
2. Hirayama K, et al. Am J Kidney Dis 2004 ; 44 : 57-63. (レベル 5)
 
3. Langford CA, et al. Arthritis Rheum 1999 ; 42 : 2666-73. (レベル 4)
 
4. Langford CA, et al. Am J Med 2003 ; 114 : 463-9. (レベル 4)
 
5. Hiemstra TF, et al. JAMA 2010 ; 304 : 2381-8. (レベル 2)
 
6. Houssiau FA, et al. Ann Rheum Dis 2010 ; 69 : 2083-9. (レベル 2)
 
7. Dooley MA, et al. N Engl J Med 2011 ; 365 : 1886-95. (レベル 2)
 
8. Levy JB, et al. Ann Intern Med 2001 ; 134 : 1033-42. (レベル 4)
 
a. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-6.
PubMed
b. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
c. Pauci-immune focal and segmental necrotizing glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 233-9.
 
d. 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
e. Hahn BH, et al. American College of Rheumatology Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012 ; 64 : 797-808.
 
f. Lupus nephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 221-32.
 
g. Anti-glomerular basement membrane antibody glomerulonephritis in KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012 (Suppl) ; 2 : 240-2.
 
P.80 掲載の参考文献
1. Itabashi M, et al. Nephron Clin Pract 2010 ; 115 : c21-c27. (レベル 4)
 
2. Ozaki S, et al. Mod Rheumatol 2012 ; 22 : 394-404. (レベル 3)
 
3. Reinhold-Keller E, et al. Arthritis Rheum 2000 ; 43 : 1021-32. (レベル 4)
 
4. Ognibene FP, et al. Am J Respir Crit Care Med 1995 ; 151 : 795-9. (レベル 4)
 
5. Guillevin L, et al. Arthritis Rheum 1997 ; 40 : 2187-98. (レベル 2)
 
6. Green H, et al. Mayo Clin Proc 2007 ; 82 : 1052-9. (レベル 1)
 
7. Stegeman CA, et al. N Engl J Med 1996 ; 4 ; 335 : 16-20. (レベル 2)
 
8. Delanaye P, et al. Nephron Clin Pract 2011 ; 119 : c187-93. (レベル 5)
 
a. 松尾清一, 他. 急速進行性腎炎症候群の診療指針第2版. 日腎会誌 2011 ; 53 : 509-55.
 
b. 尾崎承一, 他. 槇野博史, 他編. ANCA関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服事業, 2011.
 
c. Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007 ; 46 : 1615-6.
 
d. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-7.
 
e. KIDIGO Clinical Practice Guideline. Kidney Int 2012 ; Suppl 2 : 233-42.
 

書評

最近チェックした商品履歴

Loading...